Preliminary results presented from a two-year study of Artelon® CMC Spacer

Initial results from a current study aimed at evaluating treatment of thumb base osteoarthritis using Artelon® CMC Spacer demonstrates a good clinical outcome.

At Ortopediveckan 2012, the annual meeting of the Swedish Orthopaedic Association, a poster was presented from a study currently being conducted at Kärnsjukhuset in Skövde. The aim of the study is to clinically and radiologically evaluate the treatment of thumb base osteoarthritis using Artelon® CMC Spacer. The result presented includes data from 49 patients (57 operated thumbs). The poster authors conclude that Artelon® CMC Spacer is a safe alternative for the surgical treatment of thumb base osteoarthritis. The procedure is considered easy to perform and results in good thumb function with a functional joint space and satisfied patients. An improvement in the clinical outcome can be seen up to two years post-operatively.

Västra Frölunda, October 18, 2012
Kjell Thörnbring

For further information, please contact
Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone: +46 703 11 90 25

Further information is available at www.artimplant.com, where it is also possible to subscribe to future press releases: www.artimplant.com/investors-media/subscribe-to-press-releases.html

Artimplant
Artimplant is a biomaterials company focused on solutions to problems in orthopedics. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon®, meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet as well as shoulder and other soft tissue injuries.
Artimplant is a public company, listed on the NASDAQ OMX Stockholm in the Small Cap segment and in the healthcare sector.

Forward-looking statements
This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting on the Company's business, including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.
This is information that Artimplant will make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on October 18, 2012 at 4pm (Swedish time).